UK markets open in 6 hours 15 minutes

NIKKEI 225
38,774.38
+538.31(+1.41%)
HANG SENG
18,578.30
+102.38(+0.55%)
CRUDE OIL
78.93
+0.45(+0.57%)
GOLD FUTURES
2,335.80
+4.60(+0.20%)
DOW
38,852.27
+176.59(+0.46%)
Bitcoin GBP
50,581.77
-509.43(-1.00%)

Keros Therapeutics, Inc. (KROS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

60.26

-0.31

(-0.51%)

At close: 04:00PM EDT

62.52

+2.26

(+3.75%)

After hours:

04:55PM EDT

Trade prices are not sourced from all markets

All

Simply Wall St.
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
Key Insights Keros Therapeutics' estimated fair value is US$93.42 based on 2 Stage Free Cash Flow to Equity Current...
GlobeNewswire
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for KER-050 (elritercept) for
GlobeNewswire
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat pres